Frontlight ResearchEarly access
WithdrawnNo phase
A Study to Evaluate the Safety and Efficacy of PiCSO in Anterior STEMI Patients
Key facts
- Who runs it
- Miracor Medical SA
- Trial code
- Status
- Withdrawn
- Started
- 30 Mar 2023
- Expected to end
- 30 Jun 2028
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- PiCSO Impulse System
- Record updated
- 24 March 2023
- Why it stopped
- Study terminated due to lack of financing
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 31 criteriaShow less
Who can take part
- Age ≥18 years old
- Culprit lesion in proximal or mid left anterior descending artery (LAD)
- Pre-PCI TIMI flow 0, 1 or 2
- Symptoms onset time consistent with myocardial ischemia (e.g. persistent chest pain, shortness of breath, nausea/vomiting, fatigue, palpitations or syncope) ≤ 12 h
- Electrocardiogram (ECG) evidence of acute anterior myocardial infarction with ST-elevation ≥ 2 mm (0.2 mV) in 2 or more contiguous anterior precordial ECG leads (one of which should be V2, V3, or V4) in men or ≥ 1.5 mm (0.15 mV) in women
- Emergent PCI will be performed according to national and local hospital guidelines
- Consent per approved national IRB/EC specific requirements prior to the procedure
Who cannot take part
- Implants or foreign bodies in the coronary sinus
- Known previous myocardial infraction (MI)
- Previous coronary artery bypass graft (CABG)
- Known neurologic abnormality such as tumor or arteriovenous (AV) malformation, history of stroke within 6 months, any prior intracranial bleed or any permanent neurologic defect
- Administration of fibrinolytic therapy within 24 hours prior to enrollment
- Active participation in another drug or device investigational study that has not reached its primary endpoint
- Patients with definite or probable COVID-19 diagnosis > 4 weeks prior to the current MI unless they had returned to their baseline state of health after recovery from the COVID-19 illness
- Left main disease >= 50%
- Known allergy to polyurethanes, polyethylene terephthalate (PET) or stainless steel, both heparin and bivalirudin, or all of clopidogrel, ticagrelor or prasugrel that cannot be adequately pre-medicated
- Known large pericardial effusion or cardiac tamponade
- History of bleeding diathesis or known coagulopathy (including heparin-induced thrombocytopenia), any recent genitourinary (GU) or gastrointestinal (GI) bleed (within 3 months)
- Patients with cardio-pulmonary resuscitated (CPR) cardiac arrest for more than 5 min or whom baseline neurologic status is not present
- Contraindication to cardiac magnetic resonance imaging CMR (e.g. claustrophobia, foreign body implants incompatible with CMR, gadolinium intolerance)
- Chronic obstructive pulmonary disease (COPD) with home oxygen therapy or on chronic steroid therapy
- Subject has other medical illness (e.g., cancer, dementia) or known history of substance abuse (alcohol, cocaine, heroin, etc.) that may cause non-compliance with the protocol, confound the data interpretation, or is associated with limited life expectancy of less than 1 year
- Known severe kidney disease (eGFR <=30 mL/min/1.73 m2 by MDRD formula) or on hemodialysis
- Patient transferred from an outside hospital where invasive coronary procedure was attempted (including diagnostic catheterization)
- Need for treatment of any vessel other than the LAD (or its branches) during the index procedure or before the 5 ± 2 days study CMR
- Known pregnancy or breastfeeding
- Known hemodynamically relevant left to right and right to left shunt
- Cardiogenic shock (systolic blood pressure (SBP) < 90 mmHg), need for mechanical circulatory support, intravenous pressor or pre-randomization intubation
- Patient not suitable for femoral vein access
- Unconscious on presentation
- Patients under judicial protection, legal guardianship or curatorship
About the trial
What the trial wants to find out
The objective of this study is to assess the safety and efficacy of Pressure-controlled intermittent Coronary Sinus Occlusion (PiCSO) as adjunct to percutaneous coronary intervention (PCI) compared to PCI in the setting of acute anterior ST-segment elevation myocardial infarction (STEMI).
The 2 groups in the trial
- ControlNo study treatment, for comparison
This is the actual control group receiving conventional therapy, ie. percutaneous coronary intervention.
- PiCSOTreatment being tested
This arm will be treated with Pressure controlled intermittent Coronary Sinus Occlusion (PiCSO) in addition to conventional therapy (percutaneous coronary intervention).
Treatment: PiCSO Impulse System
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized Controlled Study to Evaluate the Safety and Efficacy of Pressure-controlled Intermittent Coronary Sinus Occlusion (PiCSO) in Anterior STEMI Patients With TIMI 0-2 at Presentation.
- Record updated
- 24 March 2023